Alerts
Modified Hours for Martin Luther King Jr. Day

In recognition of the upcoming Martin Luther King Jr. Day holiday, some of The University of Kansas Cancer Center’s offices will have modified hours on Monday, January 19, 2026.

More info
Staying Healthy During Influenza Season

The University of Kansas Health System is experiencing a high volume of patients seeking care for influenza and other respiratory illnesses. Whether you plan to visit the health system or not, learn how to keep yourself healthy.

More info
Skip Navigation

An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
Feasibility/Pilot

ClinicalTrials.gov Identifier:
NCT04203316

Study #:
CMH - ADVL18P1

Start Date:
May 26, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04203316

View Complete Trial Details & Eligibility at ClinicalTrials.gov

To request an appointment, call 844-323-1227.